PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 21134482-1 2011 Long acting beta(2)-adrenoceptor agonists as exemplified by salmeterol and formoterol, exhibit reassertion behaviour in isolated airway preparations. Salmeterol Xinafoate 60-70 adrenoceptor beta 2 Homo sapiens 12-32 23300522-4 2012 We show that the select ligands bind preferentially to different predicted conformers of beta(2)AR, and identify a role of beta(2)AR extracellular region as an allosteric binding site for larger drugs such as salmeterol. Salmeterol Xinafoate 209-219 adrenoceptor beta 2 Homo sapiens 89-98 23300522-4 2012 We show that the select ligands bind preferentially to different predicted conformers of beta(2)AR, and identify a role of beta(2)AR extracellular region as an allosteric binding site for larger drugs such as salmeterol. Salmeterol Xinafoate 209-219 adrenoceptor beta 2 Homo sapiens 123-132 21306583-0 2011 Formoterol and salmeterol induce a similar degree of beta2-adrenoceptor tolerance in human small airways but via different mechanisms. Salmeterol Xinafoate 15-25 adrenoceptor beta 2 Homo sapiens 53-71 21357659-2 2011 Although these agents first were used many years ago, progress in drug development has resulted in better tolerated, long-acting beta(2)-AR agonists (LABAs), such as formoterol and salmeterol. Salmeterol Xinafoate 181-191 adrenoceptor beta 2 Homo sapiens 129-139 21134482-5 2011 Results are discussed in the context of the two theories proposed to explain the long duration of action of salmeterol (binding to a specific "exosite" of the beta(2)-adrenoceptor) and formoterol (membrane deposition: micro-kinetic theory). Salmeterol Xinafoate 108-118 adrenoceptor beta 2 Homo sapiens 159-179 20590599-6 2010 KEY RESULTS: Several agonists were found to be highly subtype selective because of selective affinity (e.g. salmeterol and formoterol, for the beta(2)-adrenoceptor over the beta(1) or beta(3)), while others (e.g. isoprenaline) had little affinity-selectivity. Salmeterol Xinafoate 108-118 adrenoceptor beta 2 Homo sapiens 143-163 19719779-1 2009 It has been demonstrated that the degree of agonist-induced desensitization of the beta(2)-adrenoceptor is related to agonist efficacy (strength of signalling), whereby high-efficacy agonists (e.g. formoterol) cause more phosphorylation and internalization of the receptor than low-efficacy agonists (e.g. salmeterol). Salmeterol Xinafoate 306-316 adrenoceptor beta 2 Homo sapiens 83-103 20423350-5 2010 KEY RESULTS: Pre-incubation with beta(2)-adrenoceptor agonists (salbutamol, salmeterol, formoterol) augmented the release and mRNA expression of IL-6 and IL-8 induced by IL-1beta and IL-1beta plus histamine, whereas NF-kappaB-dependent transcription was significantly repressed, and AP-1-dependent transcription was unaffected. Salmeterol Xinafoate 76-86 adrenoceptor beta 2 Homo sapiens 33-53 19800676-2 2009 We have shown that the Arg16 allele of the adrenergic beta(2)-receptor agonist gene (ADRB2) predisposes to exacerbations in young asthmatic patients taking regular salmeterol. Salmeterol Xinafoate 164-174 adrenoceptor beta 2 Homo sapiens 85-90 19800676-10 2009 CONCLUSION: The Arg16 genotype of ADRB2 is associated with exacerbations in asthmatic children and young adults exposed daily to beta(2)-agonists, regardless of whether the exposure is to albuterol or long-acting agonists, such as salmeterol. Salmeterol Xinafoate 231-241 adrenoceptor beta 2 Homo sapiens 34-39 19594756-0 2009 Molecular mechanisms for the persistent bronchodilatory effect of the beta 2-adrenoceptor agonist salmeterol. Salmeterol Xinafoate 98-108 adrenoceptor beta 2 Homo sapiens 70-89 20003162-3 2010 Formoterol and salmeterol are two inhaled long acting beta(2) adrenoceptor agonists (LABAs), widely used for the local treatment of asthma. Salmeterol Xinafoate 15-25 adrenoceptor beta 2 Homo sapiens 54-74 19666775-3 2009 Cultured human ASM cells and isolated rabbit ASM tissues exposed for 24 h to the long-acting beta2AR agonist salmeterol exhibited impaired acute beta2AR-mediated cAMP accumulation and relaxation, respectively, together with ASM constrictor hyperresponsiveness. Salmeterol Xinafoate 109-119 adrenoceptor beta 2 Homo sapiens 93-100 19666775-3 2009 Cultured human ASM cells and isolated rabbit ASM tissues exposed for 24 h to the long-acting beta2AR agonist salmeterol exhibited impaired acute beta2AR-mediated cAMP accumulation and relaxation, respectively, together with ASM constrictor hyperresponsiveness. Salmeterol Xinafoate 109-119 adrenoceptor beta 2 Homo sapiens 145-152 17993585-5 2008 The nonselective beta AR agonist isoproterenol and the beta 2AR-selective agonists albuterol and salmeterol inhibited EGF-stimulated proliferation by more than 50%, with half-maximal effects at 4.8 nM, 110 nM, and 6.7 nM, respectively. Salmeterol Xinafoate 97-107 adrenoceptor beta 2 Homo sapiens 55-63 19201814-7 2009 In contrast to the increased binding induced by the glucocorticoids, the beta(2)AR agonists isoproterenol, albuterol, and salmeterol all induced a decrease in EGFR binding. Salmeterol Xinafoate 122-132 adrenoceptor beta 2 Homo sapiens 73-82 19059194-4 2009 Noradrenaline and the selective beta2-adrenoceptor agonists isoprenaline and salmeterol stimulated osteoclast formation and bone resorption in BM osteoblast co-cultures and increased expression of RANK-L by osteoblasts. Salmeterol Xinafoate 77-87 adrenoceptor beta 2 Homo sapiens 32-50 18586957-2 2008 In the present study, PGE(2), forskolin, and short-acting (salbutamol) and long-acting (salmeterol and formoterol) beta(2)-adrenoceptor agonists reduced the expression of ICAM-1 and the release of GM-CSF evoked by IL-1beta in ASM cells. Salmeterol Xinafoate 88-98 adrenoceptor beta 2 Homo sapiens 115-135 18512086-0 2008 An insilico approach to high altitude pulmonary edema - Molecular modeling of human beta2 adrenergic receptor and its interaction with Salmeterol & Nifedipine. Salmeterol Xinafoate 135-145 adrenoceptor beta 2 Homo sapiens 84-109 18512086-10 2008 From the present study, it can be concluded that the generated model of human beta(2) adrenergic receptor can be used for further studies related to this receptor and Salmeterol was found to have a high binding affinity with human beta(2) adrenergic receptor. Salmeterol Xinafoate 167-177 adrenoceptor beta 2 Homo sapiens 78-105 18512086-10 2008 From the present study, it can be concluded that the generated model of human beta(2) adrenergic receptor can be used for further studies related to this receptor and Salmeterol was found to have a high binding affinity with human beta(2) adrenergic receptor. Salmeterol Xinafoate 167-177 adrenoceptor beta 2 Homo sapiens 231-258 19719334-1 2009 Salmeterol/fluticasone propionate (Seretide/Advair Diskus [dry powder inhaler] or Seretide/Advair inhalation aerosol [metered-dose inhaler]) is a fixed-dose combination inhalation agent containing a long-acting beta2-adrenoceptor agonist (LABA) plus a corticosteroid. Salmeterol Xinafoate 0-10 adrenoceptor beta 2 Homo sapiens 211-229 16022567-1 2005 After the discovery of formoterol and salmeterol, new candidates for long-acting beta2-adrenoceptor agonists (LABAs) have emerged from various companies. Salmeterol Xinafoate 38-48 adrenoceptor beta 2 Homo sapiens 81-99 17901197-4 2008 In contrast, simple glucocorticoid response element (GRE)-dependent transcription induced by dexamethasone, budesonide, and fluticasone was synergistically enhanced by beta(2)-adrenoceptor agonists, including salmeterol and formoterol, to a level that could not be achieved by glucocorticoid alone. Salmeterol Xinafoate 209-219 adrenoceptor beta 2 Homo sapiens 168-188 16980556-0 2007 Salmeterol stimulation dissociates beta2-adrenergic receptor phosphorylation and internalization. Salmeterol Xinafoate 0-10 adrenoceptor beta 2 Homo sapiens 35-60 16980556-1 2007 Salmeterol is a long-acting beta(2)-adrenergic receptor (beta(2)AR) agonist commonly used in the treatment of asthma and chronic obstructive pulmonary disease. Salmeterol Xinafoate 0-10 adrenoceptor beta 2 Homo sapiens 28-55 16980556-1 2007 Salmeterol is a long-acting beta(2)-adrenergic receptor (beta(2)AR) agonist commonly used in the treatment of asthma and chronic obstructive pulmonary disease. Salmeterol Xinafoate 0-10 adrenoceptor beta 2 Homo sapiens 57-66 16980556-6 2007 We determined the capacity of salmeterol to induce beta(2)AR endocytosis, G protein-coupled receptor kinase (GRK)-site phosphorylation, degradation, and beta-arrestin2 translocation in HEK293 cells as compared with other agonists of varying intrinsic efficacies. Salmeterol Xinafoate 30-40 adrenoceptor beta 2 Homo sapiens 51-60 16772309-7 2006 CONCLUSIONS: The arginine-16 genotype of ADRB2 predisposes to exacerbations in asthmatic children and young adults, particularly in those exposed to regular salmeterol. Salmeterol Xinafoate 157-167 adrenoceptor beta 2 Homo sapiens 41-46 17030231-3 2006 OBJECTIVE: We sought to evaluate the effects of variation in the beta2-adrenergic receptor gene (ADRB2) on clinical response to salmeterol administered with fluticasone propionate. Salmeterol Xinafoate 128-138 adrenoceptor beta 2 Homo sapiens 65-90 17030231-3 2006 OBJECTIVE: We sought to evaluate the effects of variation in the beta2-adrenergic receptor gene (ADRB2) on clinical response to salmeterol administered with fluticasone propionate. Salmeterol Xinafoate 128-138 adrenoceptor beta 2 Homo sapiens 97-102 17631879-4 2007 The aim of this study was to determine whether combined fluticasone propionate, a corticosteroid, and salmeterol, a long-acting beta(2)-adrenoceptor agonist, can suppress IL-8 production by human macrophages. Salmeterol Xinafoate 102-112 adrenoceptor beta 2 Homo sapiens 128-148 17846318-6 2007 Human valve ICs treated with the selective beta2-AR agonist, salmeterol, in the presence of osteogenic medium showed a significant 5-fold decrease in the alkaline phosphatase (ALP) activity in comparison to cells treated with osteogenic medium only (P<0.05). Salmeterol Xinafoate 61-71 adrenoceptor beta 2 Homo sapiens 43-51 12578401-7 2003 Current evidence suggests that long-acting beta(2)-adrenoreceptor agonists such as salmeterol and the new long-acting anticholinergic agent tiotropium bromide are more efficacious than their shorter acting equivalents such as salbutamol and ipratropium bromide in terms of bronchodilation, improved well-being and a reduction in acute exacerbation rates. Salmeterol Xinafoate 83-93 adrenoceptor beta 2 Homo sapiens 43-65 14662724-0 2004 Desensitisation of mast cell beta2-adrenoceptor-mediated responses by salmeterol and formoterol. Salmeterol Xinafoate 70-80 adrenoceptor beta 2 Homo sapiens 29-47 14662724-4 2004 By contrast, the long-acting beta(2)-adrenoceptor agonist salmeterol (10(-10)-10(-6) m) was about two-thirds less efficacious than either formoterol or isoprenaline as an inhibitor of histamine release. Salmeterol Xinafoate 58-68 adrenoceptor beta 2 Homo sapiens 29-49 14662724-11 2004 The desensitisation induced by long-term treatments with salmeterol and formoterol was specific for beta(2)-adrenoceptor-mediated inhibition of histamine release as the inhibitory effects of alternative cAMP-elevating compounds, prostaglandin E(2), a receptor-mediated activator of adenylate cyclase, and forskolin, a direct activator of adenylate cyclase, were unaffected by desensitising treatments. Salmeterol Xinafoate 57-67 adrenoceptor beta 2 Homo sapiens 100-120 14662724-14 2004 Isoprenaline, formoterol and salmeterol (all at 10(-6) m) reduced beta(2)-adrenoceptor density by 13+/-5 (P>0.05), 49+/-13 (P<0.05) and 35+/-17% (P>0.05), respectively. Salmeterol Xinafoate 29-39 adrenoceptor beta 2 Homo sapiens 66-86 14662724-16 2004 These data indicate that long-term exposure of mast cells to both salmeterol and formoterol can cause substantial levels of desensitisation to beta(2)-adrenoceptor-mediated responses in mast cells. Salmeterol Xinafoate 66-76 adrenoceptor beta 2 Homo sapiens 143-163 15182210-9 2004 Recently, long-acting beta2-adrenoceptor agonists (beta2-agonists) such as formoterol and salmeterol and anticholinergic medications including tiotropium bromide have been developed which may further improve symptom management in COPD patients. Salmeterol Xinafoate 90-100 adrenoceptor beta 2 Homo sapiens 22-40 15219176-10 2004 CONCLUSIONS: Short-term treatment with the combined inhaled corticosteroid and long-acting beta(2)-adrenoceptor agonist fluticasone propionate/salmeterol resulted in greater control of lung function and symptoms than combined ipratropium bromide/albuterol bronchodilator therapy, in patients with COPD. Salmeterol Xinafoate 143-153 adrenoceptor beta 2 Homo sapiens 91-111 12621035-5 2003 To verify this, we evaluated the effects of a pharmacologically relevant concentration of salmeterol (2.10(-7) m), a long acting beta(2)AR agonist, on CFTR expression in primary human airway epithelial cells (HAEC). Salmeterol Xinafoate 90-100 adrenoceptor beta 2 Homo sapiens 129-138 15655528-6 2005 Those beta2-adrenoceptor agonists used clinically for the treatment of asthma and COPD were beta2 selective: 29-, 61- and 2818-fold for salbutamol, terbutaline and salmeterol over beta1, respectively. Salmeterol Xinafoate 164-174 adrenoceptor beta 2 Homo sapiens 6-24 14678342-0 2004 The arginine-16 beta2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol. Salmeterol Xinafoate 136-146 adrenoceptor beta 2 Homo sapiens 16-34 15350154-1 2004 The two inhaled long-acting beta2-adrenoceptor agonists, salmeterol and formoterol, have been studied extensively since their introduction in the early 1990s. Salmeterol Xinafoate 57-67 adrenoceptor beta 2 Homo sapiens 28-46 12897749-8 2003 RESULTS: Rolipram unmasked the inhibitory effect of beta(2)-adrenoceptor stimulation with salmeterol and significantly attenuated the stimulated release of AA and subsequent LTC(4). Salmeterol Xinafoate 90-100 adrenoceptor beta 2 Homo sapiens 52-72 12810191-2 2003 There is increasing evidence that long-acting agents, such as the beta(2)-adrenoceptor agonists salmeterol and formeterol, and the new anticholinergic tiotropium bromide provide a better therapeutic option. Salmeterol Xinafoate 96-106 adrenoceptor beta 2 Homo sapiens 66-86 14720047-1 2002 Salmeterol/fluticasone propionate is a fixed-dose combination of the long-acting beta2-adrenoceptor agonist salmeterol and the corticosteroid fluticasone propionate and is inhaled via the Diskus powder inhaler. Salmeterol Xinafoate 0-10 adrenoceptor beta 2 Homo sapiens 81-99 14510626-12 2003 The main pharmacological difference between the agents is that formoterol is a full beta2-adrenergic agonist, whereas salmeterol is a partial agonist at the beta2-adrenoceptor and has a unique pharmacological action. Salmeterol Xinafoate 118-128 adrenoceptor beta 2 Homo sapiens 157-175 12503692-10 2002 In conclusion, a novel antineutrophilic effect of the inhaled long-acting beta2-adrenergic receptor agonist, salmeterol, in mild asthma is reported. Salmeterol Xinafoate 109-119 adrenoceptor beta 2 Homo sapiens 74-99 14720033-1 2002 Beta2-adrenoceptor agonists (beta2-agonists) such as albuterol (salbutamol) and terbutaline and their long-acting analogs salmeterol and formoterol are widely used as bronchodilators in the treatment of asthma. Salmeterol Xinafoate 122-132 adrenoceptor beta 2 Homo sapiens 0-18 12236842-1 2002 The established place of regular long-acting beta2-adrenoceptor agonists at step 3 in asthma management guidelines has evolved as a consequence of evidence showing additive effects of salmeterol and formoterol on exacerbation rates, resulting in a putative inhaled corticosteroid sparing effect. Salmeterol Xinafoate 184-194 adrenoceptor beta 2 Homo sapiens 45-63 14720076-1 2002 Salmeterol and formoterol are both long-acting beta(2)-adrenoceptor agonists (beta(2)-agonists). Salmeterol Xinafoate 0-10 adrenoceptor beta 2 Homo sapiens 47-67 11419918-1 2001 UNLABELLED: Inhaled salmeterol is a long-acting, selective beta2-adrenoceptor agonist bronchodilator. Salmeterol Xinafoate 20-30 adrenoceptor beta 2 Homo sapiens 59-77 11825095-1 2002 Salmeterol is an inhaled long-acting selective beta(2)-adrenoceptor agonist that is commercially available as the xinafoate (1-hydroxy-2-naphthoic acid) salt of the racemic mixture of the two optical isomers, (R)- and (S)-, of salmeterol. Salmeterol Xinafoate 0-10 adrenoceptor beta 2 Homo sapiens 47-67 10950895-3 2000 METHODS: In a retrospective analysis of previously published data we have examined relationships between polymorphisms at codons 16 and 27 of the beta(2) adrenoceptor and clinical outcomes in a randomised, placebo controlled, crossover trial of regularly scheduled salbutamol and salmeterol in 115 patients with mild to moderate asthma. Salmeterol Xinafoate 280-290 adrenoceptor beta 2 Homo sapiens 146-166 10471277-0 1999 Probing the salmeterol binding site on the beta 2-adrenergic receptor using a novel photoaffinity ligand, [(125)I]iodoazidosalmeterol. Salmeterol Xinafoate 12-22 adrenoceptor beta 2 Homo sapiens 43-69 10936119-0 2000 Functional antagonism with formoterol and salmeterol in asthmatic patients expressing the homozygous glycine-16 beta(2)-adrenoceptor polymorphism. Salmeterol Xinafoate 42-52 adrenoceptor beta 2 Homo sapiens 112-132 10516654-7 1999 However, all of the beta2 adrenoceptor agonists produced increases in CRE-driven luciferase activity, in cultured HASM transfected with the vector p6CRE/luc, which were equivalent or greater (salmeterol) than those seen with isoprenaline. Salmeterol Xinafoate 192-202 adrenoceptor beta 2 Homo sapiens 20-38 10471277-1 1999 Salmeterol is a long-acting beta2-adrenergic receptor (beta 2AR) agonist used clinically to treat asthma. Salmeterol Xinafoate 0-10 adrenoceptor beta 2 Homo sapiens 28-53 10471277-1 1999 Salmeterol is a long-acting beta2-adrenergic receptor (beta 2AR) agonist used clinically to treat asthma. Salmeterol Xinafoate 0-10 adrenoceptor beta 2 Homo sapiens 55-63 10471277-3 1999 To determine the position of the phenyl ring of the aralkyloxyalkyl side chain of salmeterol in the beta 2AR binding site, we designed and synthesized the agonist photoaffinity label [(125)I]iodoazidosalmeterol ([125I]IAS). Salmeterol Xinafoate 82-92 adrenoceptor beta 2 Homo sapiens 100-108 10492055-0 1999 Comparative trough effects of formoterol and salmeterol on lymphocyte beta2-adrenoceptor--regulation and bronchodilatation. Salmeterol Xinafoate 45-55 adrenoceptor beta 2 Homo sapiens 70-88 10492055-1 1999 OBJECTIVES: The primary aim of the present study was to evaluate comparative trough effects of formoterol and salmeterol on beta2-adrenoceptor regulation and bronchodilator response after regular twice-daily treatment, with a secondary aim to evaluate any possible association with beta2-adrenoceptor polymorphism. Salmeterol Xinafoate 110-120 adrenoceptor beta 2 Homo sapiens 124-142 10515401-1 1999 Salmeterol xinafoate is an inhaled long-acting beta2-adrenoceptor agonist recently introduced for the treatment of asthma. Salmeterol Xinafoate 0-20 adrenoceptor beta 2 Homo sapiens 47-65 9877002-1 1998 BACKGROUND: Salmeterol xinafoate is a highly selective beta2-adrenoceptor for the maintenance treatment of asthma in adults and children. Salmeterol Xinafoate 12-32 adrenoceptor beta 2 Homo sapiens 55-73 9873044-3 1999 Here, we describe the ligand-independent activation of GR by the beta2-adrenergic receptor (beta2-AR) agonists, salbutamol and salmeterol, in primary human lung fibroblasts and vascular smooth muscle cells. Salmeterol Xinafoate 127-137 adrenoceptor beta 2 Homo sapiens 65-90 9873044-3 1999 Here, we describe the ligand-independent activation of GR by the beta2-adrenergic receptor (beta2-AR) agonists, salbutamol and salmeterol, in primary human lung fibroblasts and vascular smooth muscle cells. Salmeterol Xinafoate 127-137 adrenoceptor beta 2 Homo sapiens 92-100 9873044-5 1999 Treatment of the cells with the beta2-AR agonists, salbutamol or salmeterol, resulted in translocation of GR into the nucleus beginning at 30 min, as shown by immunohistochemistry and Western blotting of cytosolic and nuclear cell extracts. Salmeterol Xinafoate 65-75 adrenoceptor beta 2 Homo sapiens 32-40 9873044-9 1999 The effects of the beta2-AR agonists, salbutamol and salmeterol, were dependent upon binding to the beta2-AR, because blocking of beta2-AR with propranolol abrogated GR activation. Salmeterol Xinafoate 53-63 adrenoceptor beta 2 Homo sapiens 19-27 9873044-9 1999 The effects of the beta2-AR agonists, salbutamol and salmeterol, were dependent upon binding to the beta2-AR, because blocking of beta2-AR with propranolol abrogated GR activation. Salmeterol Xinafoate 53-63 adrenoceptor beta 2 Homo sapiens 100-108 9873044-9 1999 The effects of the beta2-AR agonists, salbutamol and salmeterol, were dependent upon binding to the beta2-AR, because blocking of beta2-AR with propranolol abrogated GR activation. Salmeterol Xinafoate 53-63 adrenoceptor beta 2 Homo sapiens 100-108 9831907-0 1998 Influence of receptor number on the stimulation by salmeterol of gene transcription in CHO-K1 cells transfected with the human beta2-adrenoceptor. Salmeterol Xinafoate 51-61 adrenoceptor beta 2 Homo sapiens 127-145 9596305-3 1998 The aim of this study was to evaluate the potential short-term, cardiovascular side effects of salmeterol, a long-acting and highly selective beta2-adrenoceptor agonist. Salmeterol Xinafoate 95-105 adrenoceptor beta 2 Homo sapiens 142-160 9765503-7 1998 These results indicate that Tyr308 in TMD VII is the major amino acid conferring the beta2-selective binding of salmeterol to the beta2AR and that the position of the ether oxygen in the side chain is also important for beta2-selective binding. Salmeterol Xinafoate 112-122 adrenoceptor beta 2 Homo sapiens 130-137 9765503-8 1998 A three-dimensional model of the salmeterol-beta2AR complex shows that the phenyl group of Tyr308 interacts with methylene groups near the protonated amine of salmeterol and the ether oxygen interacts with Tyr316. Salmeterol Xinafoate 33-43 adrenoceptor beta 2 Homo sapiens 44-51 9765503-0 1998 Identification of a key amino acid of the beta2-adrenergic receptor for high affinity binding of salmeterol. Salmeterol Xinafoate 97-107 adrenoceptor beta 2 Homo sapiens 42-67 9765503-3 1998 The affinity of salmeterol was slightly decreased (32-fold) by replacement of TMD II of the beta2AR with the homologous region of the beta1AR; the affinity was strongly decreased (1870-fold) for the beta2AR with TMD VII of the beta1AR. Salmeterol Xinafoate 16-26 adrenoceptor beta 2 Homo sapiens 92-99 9765503-3 1998 The affinity of salmeterol was slightly decreased (32-fold) by replacement of TMD II of the beta2AR with the homologous region of the beta1AR; the affinity was strongly decreased (1870-fold) for the beta2AR with TMD VII of the beta1AR. Salmeterol Xinafoate 16-26 adrenoceptor beta 2 Homo sapiens 199-206 9765503-4 1998 The affinity of salmeterol was partially restored by the introduction of TMD VII, but not TMD II, of the beta2AR into the beta1AR. Salmeterol Xinafoate 16-26 adrenoceptor beta 2 Homo sapiens 105-112 9765503-6 1998 Two salmeterol derivatives with the ether oxygen at different positions in the side chain showed 33- and 64-fold decreased affinities for the wild-type beta2AR, and a derivative with no ether oxygen showed 147-fold decreased affinity for the wild-type beta2AR. Salmeterol Xinafoate 4-14 adrenoceptor beta 2 Homo sapiens 152-159 9765503-6 1998 Two salmeterol derivatives with the ether oxygen at different positions in the side chain showed 33- and 64-fold decreased affinities for the wild-type beta2AR, and a derivative with no ether oxygen showed 147-fold decreased affinity for the wild-type beta2AR. Salmeterol Xinafoate 4-14 adrenoceptor beta 2 Homo sapiens 252-259 9648961-1 1998 Long-acting beta2-adrenoceptor agonists such as salmeterol reduce airway responsiveness for at least 12 h, but this effect seems to decrease with regular use. Salmeterol Xinafoate 48-58 adrenoceptor beta 2 Homo sapiens 12-30 9554653-4 1998 DATA SYNTHESIS: Salmeterol and formoterol are potent and selective beta2-adrenoceptor agonists with durations of action >12 h. Their major differences are that formoterol has a rapid onset of action and is a partial agonist of high intrinsic efficacy, whereas salmeterol has a delayed onset and is a partial agonist of low intrinsic efficacy. Salmeterol Xinafoate 16-26 adrenoceptor beta 2 Homo sapiens 67-85 19479397-1 1997 The introduction of long-acting beta(2)-adrenoceptor agonists such as salmeterol and formoterol has opened new perspectives for the treatment of asthma and, possibly, also COPD. Salmeterol Xinafoate 70-80 adrenoceptor beta 2 Homo sapiens 32-52 9594486-1 1998 Salmeterol xinafoate is a potent and highly selective beta 2-adrenoreceptor agonist with a duration of action greater than 12 hours. Salmeterol Xinafoate 0-20 adrenoceptor beta 2 Homo sapiens 54-75 9525449-1 1998 OBJECTIVE: We have previously found that beta2-adrenoceptor downregulation and bronchodilator desensitization to albuterol occurred at 36 hours after stopping regular treatment with twice daily salmeterol. Salmeterol Xinafoate 194-204 adrenoceptor beta 2 Homo sapiens 41-59 9517390-0 1998 Salmeterol-induced desensitization, internalization and phosphorylation of the human beta2-adrenoceptor. Salmeterol Xinafoate 0-10 adrenoceptor beta 2 Homo sapiens 85-103 9517390-5 1998 We have compared the activation and desensitization of human beta2-adrenoceptor stimulation of adenylyl cyclase induced by salmeterol, adrenaline and salbutamol in a human lung epithelial line, BEAS-2B, expressing beta2-adrenoceptor levels of 40-70 fmol mg(-1), and in human embryonic kidney (HEK) 293 cell lines expressing 2-10 pmol mg(-1). Salmeterol Xinafoate 123-133 adrenoceptor beta 2 Homo sapiens 61-79 9517390-7 1998 Salmeterol pretreatment of these cells induced a rapid and stable activation of adenylyl cyclase activity which resisted extensive washing and beta2-adrenoceptor antagonist blockade, consistent with binding to a receptor exosite and/or to partitioning into membrane lipid. Salmeterol Xinafoate 0-10 adrenoceptor beta 2 Homo sapiens 143-161 9517390-12 1998 Our data suggest that the reduction in the rapid phase of desensitization of beta2-adrenoceptors after treatment with salmeterol or salbutamol is caused by a decrease in the rate of beta2-adrenoceptor kinase (betaARK) phosphorylation and internalization. Salmeterol Xinafoate 118-128 adrenoceptor beta 2 Homo sapiens 77-95 9535032-2 1998 The long-acting beta2-adrenoceptor agonist, salmeterol (10(-9)-10(-5) M), inhibited the IgE-mediated release of histamine from human lung mast cells (HLMC) in a dose-dependent fashion. Salmeterol Xinafoate 44-54 adrenoceptor beta 2 Homo sapiens 16-34 9596106-1 1998 The aim of this study was to systematically compare the interaction of the long-acting beta2-adrenoceptor agonists formoterol and salmeterol with short-acting beta2-adrenoceptor agonists in contracted human bronchi. Salmeterol Xinafoate 130-140 adrenoceptor beta 2 Homo sapiens 159-177 9568547-1 1997 Salmeterol, a long-acting beta 2-adrenoceptor agonist, also possesses some anti-inflammatory properties, but whether eosinophils are the target of such action has been equivocal. Salmeterol Xinafoate 0-10 adrenoceptor beta 2 Homo sapiens 26-45 9262535-1 1997 Salmeterol is a highly selective beta 2-adrenoreceptor agonist with a long duration of action--as long as 12 hours or more. Salmeterol Xinafoate 0-10 adrenoceptor beta 2 Homo sapiens 33-54 9257086-2 1997 Salmeterol xinafoate is a selective beta 2-adrenoceptor agonist indicated for the maintenance treatment of adults and children with asthma. Salmeterol Xinafoate 0-20 adrenoceptor beta 2 Homo sapiens 36-55 9056046-8 1997 For predominantly beta 2-AR agonist such as salmeterol and salbutamol, potentiation of exercise hyperkalaemia occurs. Salmeterol Xinafoate 44-54 adrenoceptor beta 2 Homo sapiens 18-27 9230722-1 1997 There is evidence that downregulation and desensitization of airway beta 2-adrenoceptors (beta 2-AR) develops after continuous exposure to long-acting beta 2-agonists such as formoterol and salmeterol. Salmeterol Xinafoate 190-200 adrenoceptor beta 2 Homo sapiens 68-88 9230722-1 1997 There is evidence that downregulation and desensitization of airway beta 2-adrenoceptors (beta 2-AR) develops after continuous exposure to long-acting beta 2-agonists such as formoterol and salmeterol. Salmeterol Xinafoate 190-200 adrenoceptor beta 2 Homo sapiens 90-99 9184473-0 1997 The interaction between salmeterol and the beta 2-adrenoceptor protein. Salmeterol Xinafoate 24-34 adrenoceptor beta 2 Homo sapiens 43-62 9142928-6 1997 Preincubation of neutrophils with the long-acting beta2-adrenergic receptor agonist salmeterol (in the presence of IBMX) inhibited their fMLP-stimulated adhesion to epithelial cells, whereas pretreatment of epithelial cells did not influence the adhesion process. Salmeterol Xinafoate 84-94 adrenoceptor beta 2 Homo sapiens 50-75 9093358-0 1997 Beta 2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol. Salmeterol Xinafoate 66-76 adrenoceptor beta 2 Homo sapiens 0-19 9056046-10 1997 beta 2-AR partial agonist activity may also be expressed as antagonism in the presence of an exogenous full agonist, as for example attenuation of fenoterol induced responses by salmeterol. Salmeterol Xinafoate 178-188 adrenoceptor beta 2 Homo sapiens 0-9 9007523-7 1996 Although treatment with salbutamol for 3 h did not change beta 2-adrenoceptor density, both salmeterol and formoterol reduced beta 2-adrenoceptor density, and exposure to each agonist for 24 h reduced beta 2-adrenoceptor density at all concentrations. Salmeterol Xinafoate 92-102 adrenoceptor beta 2 Homo sapiens 126-145 9007523-3 1996 We examined the effects of three selective beta 2-adrenoceptor agonists, salbutamol, salmeterol and formoterol on beta 2-adrenoceptor binding and mRNA levels in human lung in vitro. Salmeterol Xinafoate 85-95 adrenoceptor beta 2 Homo sapiens 114-133 9344832-2 1997 Since monocytes and lymphocytes play a major pathogenetic role in allergic asthma, this study was designed to evaluate the hypothesis that salmeterol, a beta 2-adrenoceptor agonist with a long duration of action, could inhibit in vitro the allergen-induced activation of blood mononuclear cells (BMCs). Salmeterol Xinafoate 139-149 adrenoceptor beta 2 Homo sapiens 153-172 9007523-7 1996 Although treatment with salbutamol for 3 h did not change beta 2-adrenoceptor density, both salmeterol and formoterol reduced beta 2-adrenoceptor density, and exposure to each agonist for 24 h reduced beta 2-adrenoceptor density at all concentrations. Salmeterol Xinafoate 92-102 adrenoceptor beta 2 Homo sapiens 126-145 8885698-1 1996 The four beta 2-adrenoceptor agonists, clenbuterol, bambuterol, formoterol and salmeterol, are all long-acting bronchodilators, that have distinct mechanisms for their extended durations of action. Salmeterol Xinafoate 79-89 adrenoceptor beta 2 Homo sapiens 9-28 8622643-0 1996 Comparison of duration of agonist action at beta 1- and beta 2- adrenoceptors in C6 glioma cells: evidence that the long duration of action of salmeterol is specific to the beta 2-adrenoceptor. Salmeterol Xinafoate 143-153 adrenoceptor beta 2 Homo sapiens 173-192 8853286-2 1996 Formoterol and salmeterol are the first members of a new generation of long-acting beta(2)-adrenoceptor agonists for inhalation. Salmeterol Xinafoate 15-25 adrenoceptor beta 2 Homo sapiens 83-103 8853286-14 1996 Like all other beta(2)-adrenoceptor agonists in current clinical use, formoterol and salmeterol comprise racemic mixtures. Salmeterol Xinafoate 85-95 adrenoceptor beta 2 Homo sapiens 15-35 8723736-1 1996 Salmeterol xinafoate (Serevent) is a long-acting beta2-adrenoceptor agonist, used in the treatment of asthma, that has bronchodilator and anti-inflammatory action. Salmeterol Xinafoate 0-20 adrenoceptor beta 2 Homo sapiens 49-67 8723736-1 1996 Salmeterol xinafoate (Serevent) is a long-acting beta2-adrenoceptor agonist, used in the treatment of asthma, that has bronchodilator and anti-inflammatory action. Salmeterol Xinafoate 22-30 adrenoceptor beta 2 Homo sapiens 49-67 8655889-1 1996 BACKGROUND: Inhalation of a single dose of the long-acting beta 2-adrenoceptor agonist salmeterol protects against methacholine-induced airway obstruction and other bronchoconstricting stimuli for at least 12 hours. Salmeterol Xinafoate 87-97 adrenoceptor beta 2 Homo sapiens 59-78 7858856-14 1994 Salmeterol inhibits, competitively, relaxant responses to beta 2-adrenoceptor agonists with higher efficacy. Salmeterol Xinafoate 0-10 adrenoceptor beta 2 Homo sapiens 58-77 8658370-0 1996 Evaluation of the beta 2 adrenoceptor agonist/antagonist activity of formoterol and salmeterol. Salmeterol Xinafoate 84-94 adrenoceptor beta 2 Homo sapiens 18-37 7616798-6 1995 There was a significant reduction in lymphocyte beta-2 adrenoceptor density after salmeterol compared with placebo and run-in. Salmeterol Xinafoate 82-92 adrenoceptor beta 2 Homo sapiens 48-67 8746998-1 1996 The mechanisms behind the long duration of bronchodilating action of the beta 2-adrenoceptor agonists formoterol and salmeterol are only partially understood. Salmeterol Xinafoate 117-127 adrenoceptor beta 2 Homo sapiens 73-92 8746998-4 1996 Both formoterol and salmeterol display a higher lipophilicity and have a higher affinity, selectivity, and potency than most short-acting agonists at the beta 2-adrenoceptor. Salmeterol Xinafoate 20-30 adrenoceptor beta 2 Homo sapiens 154-173 7752089-1 1995 Salmeterol (SALM) is a long-acting beta 2 adrenoceptor agonist that causes prolonged relaxation of airway smooth muscle. Salmeterol Xinafoate 0-10 adrenoceptor beta 2 Homo sapiens 35-54 7858856-16 1994 This contrasts with results obtained with sulfonterol and suggests that salmeterol interacts with the beta 2-adrenoceptor in a complex way. Salmeterol Xinafoate 72-82 adrenoceptor beta 2 Homo sapiens 102-121 7909853-1 1994 OBJECTIVE: To compare the efficacy and safety of inhaled salmeterol xinafoate, a long-acting beta 2-adrenoceptor agonist, with that of albuterol, a short-acting inhaled beta 2-agonist, in the treatment of asthma. Salmeterol Xinafoate 57-77 adrenoceptor beta 2 Homo sapiens 93-112 7521712-0 1994 Influence of salmeterol, a long-acting beta 2-adrenoceptor agonist, on IgE-mediated histamine release from human basophils. Salmeterol Xinafoate 13-23 adrenoceptor beta 2 Homo sapiens 39-58 7909285-1 1994 STUDY OBJECTIVE: A dose-ranging study was conducted to evaluate the efficacy and safety of a new long-acting, selective beta 2-adrenoceptor agonist, salmeterol. Salmeterol Xinafoate 149-159 adrenoceptor beta 2 Homo sapiens 120-139 7914175-1 1994 New long-acting beta 2-adrenoceptor agonists, salmeterol and formoterol, have recently been marketed for treatment of asthma, but studies comparing the clinical efficacy of the two drugs have not been published. Salmeterol Xinafoate 46-56 adrenoceptor beta 2 Homo sapiens 16-35 7912202-3 1994 The comparative pharmacology, and molecular modelling of these drugs and of the beta 2-adrenoceptor and its ligand binding core have cast doubt on the exosite/exoceptor model previously proposed to explain the behaviour of salmeterol. Salmeterol Xinafoate 223-233 adrenoceptor beta 2 Homo sapiens 80-99 7912202-4 1994 We present evidence supporting a unifying hypothesis that the duration of action both of formoterol and salmeterol is determined principally by their physicochemical interactions with membrane lipid bilayers (plasmalemma diffusion microkinetic model), rather than putative distinct exosite/exoceptor binding sites in or near the beta 2-adrenoceptor. Salmeterol Xinafoate 104-114 adrenoceptor beta 2 Homo sapiens 329-348 7521712-1 1994 Salmeterol, a long-acting beta 2-adrenoceptor agonist, prevents early and late asthmatic responses in atopic asthmatics and inhibits the release of inflammatory mediators from various cells and tissues. Salmeterol Xinafoate 0-10 adrenoceptor beta 2 Homo sapiens 26-45 8099695-2 1993 Salmeterol is > 10,000 times more lipophilic than salbutamol and has greater affinity for the beta 2-adrenoceptor. Salmeterol Xinafoate 0-10 adrenoceptor beta 2 Homo sapiens 97-116 7902176-0 1993 Salmeterol, a long-acting beta 2-adrenoceptor agonist mediating cyclic AMP accumulation in a neuronal cell line. Salmeterol Xinafoate 0-10 adrenoceptor beta 2 Homo sapiens 26-45 7902176-7 1993 The beta 2-adrenoceptor antagonist, ICI 118551, inhibited the responses to both salmeterol (apparent KD 2.2 nM) and isoprenaline (apparent KD 1.6 nM). Salmeterol Xinafoate 80-90 adrenoceptor beta 2 Homo sapiens 4-23 7902176-13 1993 Whereas salmeterol has a slow onset of action in airway smooth muscle compared to other beta 2-adrenoceptor agonists, in B50 monolayers both salmeterol and isoprenaline produced a rapid increase in cyclic AMP accumulation (t1/2 1.1 min and 0.4 min respectively). Salmeterol Xinafoate 141-151 adrenoceptor beta 2 Homo sapiens 88-107 8103622-1 1993 Formoterol and salmeterol are chemically distinct, highly selective beta-2-adrenoceptor agonists developed to provide sustained (12h+) relief of airway obstruction in diseases such as asthma. Salmeterol Xinafoate 15-25 adrenoceptor beta 2 Homo sapiens 68-87 8103622-4 1993 Salmeterol, but not formoterol, behaves as a beta-adrenoceptor antagonist in some experimental models due to its considerably weaker efficacy at the beta 2-adrenoceptor in vitro although their are no established clinical consequences of this antagonism. Salmeterol Xinafoate 0-10 adrenoceptor beta 2 Homo sapiens 149-168 8093705-1 1993 BACKGROUND: Salmeterol is a new inhaled selective beta 2-adrenergic receptor agonist with a long duration of action. Salmeterol Xinafoate 12-22 adrenoceptor beta 2 Homo sapiens 50-76 7905340-7 1993 Relaxant responses to salmeterol were fully reversed by the selective beta 2-adrenoceptor blocking drug, ICI 118551, demonstrating the involvement of beta 2-adrenoceptors. Salmeterol Xinafoate 22-32 adrenoceptor beta 2 Homo sapiens 70-89 1357554-2 1992 We compared a new long-acting, inhaled beta 2-adrenoceptor agonist, salmeterol, with a short-acting beta 2-agonist, albuterol, in the treatment of mild-to-moderate asthma. Salmeterol Xinafoate 68-78 adrenoceptor beta 2 Homo sapiens 39-58 1359777-1 1992 Salmeterol xinafoate, like salbutamol (albuterol), is a saligenin derivative, and a selective beta 2-adrenoceptor agonist. Salmeterol Xinafoate 0-20 adrenoceptor beta 2 Homo sapiens 94-113 1357550-0 1992 Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma. Salmeterol Xinafoate 64-74 adrenoceptor beta 2 Homo sapiens 35-54 1346794-1 1992 Salmeterol (SM) is a novel beta 2-adrenoceptor agonist with a duration of action in excess of 12 hours. Salmeterol Xinafoate 0-10 adrenoceptor beta 2 Homo sapiens 27-46 1346794-1 1992 Salmeterol (SM) is a novel beta 2-adrenoceptor agonist with a duration of action in excess of 12 hours. Salmeterol Xinafoate 12-14 adrenoceptor beta 2 Homo sapiens 27-46 1675178-1 1991 New long-acting beta 2-adrenoceptor agonists, formoterol and salmeterol, may soon appear in several European countries for treatment of asthma. Salmeterol Xinafoate 61-71 adrenoceptor beta 2 Homo sapiens 16-35 1723379-2 1991 Salmeterol xinafoate, like salbutamol (albuterol), is a saligenin derivative, and a selective beta 2-adrenoceptor agonist. Salmeterol Xinafoate 0-20 adrenoceptor beta 2 Homo sapiens 94-113 1686530-3 1991 Salmeterol, a new long-acting, beta 2-adrenoceptor agonist has been developed and shown to induce persistent relaxation of airways smooth muscle in vitro and sustained bronchodilatation in vivo, and to have significant anti-inflammatory activity in the lung, suppressing inflammatory mediator release and inflammatory cell infiltration and inhibiting vascular permeability and oedema formation. Salmeterol Xinafoate 0-10 adrenoceptor beta 2 Homo sapiens 31-50 1975162-2 1990 Salmeterol (SM) is a new beta 2-adrenoceptor agonist for inhaled use that has been shown to produce long-lasting bronchodilation in asthmatic patients. Salmeterol Xinafoate 0-10 adrenoceptor beta 2 Homo sapiens 25-44 1975162-2 1990 Salmeterol (SM) is a new beta 2-adrenoceptor agonist for inhaled use that has been shown to produce long-lasting bronchodilation in asthmatic patients. Salmeterol Xinafoate 12-14 adrenoceptor beta 2 Homo sapiens 25-44 30327561-1 2018 Salmeterol is a partial agonist for the beta2 adrenergic receptor (beta2AR) and the first long-acting beta2AR agonist to be widely used clinically for the treatment of asthma and chronic obstructive pulmonary disease. Salmeterol Xinafoate 0-10 adrenoceptor beta 2 Homo sapiens 40-65 34334369-12 2021 Significance Statement The cell membrane"s functional role behind the duration of action of long-acting beta2-adrenergic receptor (beta2-AR) agonists such as salmeterol has been a subject of debate for a long time. Salmeterol Xinafoate 158-168 adrenoceptor beta 2 Homo sapiens 104-129 2904183-0 1988 Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients. Salmeterol Xinafoate 0-10 adrenoceptor beta 2 Homo sapiens 38-57 2904183-1 1988 Salmeterol is a new inhaled beta 2 adrenoceptor agonist, which has been shown in animal experiments to produce a more prolonged bronchodilator effect than currently available beta 2 adrenoceptor agonists. Salmeterol Xinafoate 0-10 adrenoceptor beta 2 Homo sapiens 28-47 30327561-1 2018 Salmeterol is a partial agonist for the beta2 adrenergic receptor (beta2AR) and the first long-acting beta2AR agonist to be widely used clinically for the treatment of asthma and chronic obstructive pulmonary disease. Salmeterol Xinafoate 0-10 adrenoceptor beta 2 Homo sapiens 67-74 30327561-1 2018 Salmeterol is a partial agonist for the beta2 adrenergic receptor (beta2AR) and the first long-acting beta2AR agonist to be widely used clinically for the treatment of asthma and chronic obstructive pulmonary disease. Salmeterol Xinafoate 0-10 adrenoceptor beta 2 Homo sapiens 102-109 30327561-3 2018 To understand its unusual pharmacological action and partial agonism, we obtained the crystal structure of salmeterol-bound beta2AR in complex with an active-state-stabilizing nanobody. Salmeterol Xinafoate 107-117 adrenoceptor beta 2 Homo sapiens 124-131 29653961-2 2018 Operational model-fitting established that the long-acting beta2-adrenoceptor agonists (LABA) indacaterol, salmeterol, formoterol, and picumeterol were full agonists on BEAS-2B cells transfected with a cAMP-response element reporter but differed in efficacy (indacaterol >= formoterol > salmeterol >= picumeterol). Salmeterol Xinafoate 293-303 adrenoceptor beta 2 Homo sapiens 59-77 29653961-2 2018 Operational model-fitting established that the long-acting beta2-adrenoceptor agonists (LABA) indacaterol, salmeterol, formoterol, and picumeterol were full agonists on BEAS-2B cells transfected with a cAMP-response element reporter but differed in efficacy (indacaterol >= formoterol > salmeterol >= picumeterol). Salmeterol Xinafoate 107-117 adrenoceptor beta 2 Homo sapiens 59-77 23375225-1 2013 A novel class of dual pharmacology bronchodilators targeting both beta(2)-adrenoceptor and PDE4 was designed and synthesised by combining the pharmacophores of salmeterol and roflumilast or phthalazinone. Salmeterol Xinafoate 160-170 adrenoceptor beta 2 Homo sapiens 66-86 27222010-9 2016 Finally, the long-acting ADRB2-specific agonist, salmeterol, markedly reduced the cytokine secretion capacity of CD8(+) T cells in response to infection with vesicular stomatitis virus. Salmeterol Xinafoate 49-59 adrenoceptor beta 2 Homo sapiens 25-30 26049917-2 2015 Long-acting beta2-adrenoceptor agonists, formoterol and salmeterol, represent a milestone in the treatments of chronic obstructive lung diseases. Salmeterol Xinafoate 56-66 adrenoceptor beta 2 Homo sapiens 12-30 25799096-8 2015 beta2-AR tachyphylaxis was induced with salbutamol, salmeterol and formoterol on guinea pig tracheas. Salmeterol Xinafoate 52-62 adrenoceptor beta 2 Homo sapiens 0-8 24681963-0 2014 The effects of a Gly16Arg ADRB2 polymorphism on responses to salmeterol or montelukast in Japanese patients with mild persistent asthma. Salmeterol Xinafoate 61-71 adrenoceptor beta 2 Homo sapiens 26-31 24561123-8 2014 Our results suggest that beta2AR activation with salmeterol can induce the dissociation of heterotrimeric G-proteins, Galphabetagamma, into Galpha and Gbetagamma subunits, which in turn activates downstream signaling cascades. Salmeterol Xinafoate 49-59 adrenoceptor beta 2 Homo sapiens 25-32 24461901-2 2014 We aimed to establish whether ADRB2 polymorphisms differentially affected COPD exacerbation outcomes in response to tiotropium versus salmeterol. Salmeterol Xinafoate 134-144 adrenoceptor beta 2 Homo sapiens 30-35 24228710-0 2013 Loss of salmeterol bronchoprotection against exercise in relation to ADRB2 Arg16Gly polymorphism and exhaled nitric oxide. Salmeterol Xinafoate 8-18 adrenoceptor beta 2 Homo sapiens 69-74 28097668-1 2017 Salmeterol is a man-made beta-2-adrenergic receptor agonist used to relieve bronchospasm associated with inflammatory airway disease in horses. Salmeterol Xinafoate 0-10 adrenoceptor beta 2 Homo sapiens 25-51 28398147-0 2017 Salmeterol, a Long-Acting beta2-Adrenergic Receptor Agonist, Inhibits Macrophage Activation by Lipopolysaccharide From Porphyromonas gingivalis. Salmeterol Xinafoate 0-10 adrenoceptor beta 2 Homo sapiens 26-51 28398147-1 2017 BACKGROUND: Salmeterol is a long-acting beta2-adrenergic receptor agonist used to treat chronic obstructive pulmonary disease. Salmeterol Xinafoate 12-22 adrenoceptor beta 2 Homo sapiens 40-65 27885204-0 2016 GENETIC INTERACTIONS BETWEEN ADRB2 AND PTGER4 ON RESPONSES TO SALMETEROL OR MONTELUKAST IN JAPANESE PATIENTS WITH MILD PERSISTENT ASTHMA. Salmeterol Xinafoate 62-72 adrenoceptor beta 2 Homo sapiens 29-34 27885204-8 2016 CONCLUSION: Our findings suggested that the interactions between two genetic loci at ADRB2 and PTGER4 is important in determining the differential response to salmeterol versus montelukast in patients with chronic adult asthma. Salmeterol Xinafoate 159-169 adrenoceptor beta 2 Homo sapiens 85-90 25784721-1 2015 Salmeterol is a long-acting beta2-adrenergic receptor (beta2AR) agonist that is widely used as a bronchodilator for the treatment of persistent asthma and chronic obstructive pulmonary disease in conjunction with steroids. Salmeterol Xinafoate 0-10 adrenoceptor beta 2 Homo sapiens 28-53 25784721-1 2015 Salmeterol is a long-acting beta2-adrenergic receptor (beta2AR) agonist that is widely used as a bronchodilator for the treatment of persistent asthma and chronic obstructive pulmonary disease in conjunction with steroids. Salmeterol Xinafoate 0-10 adrenoceptor beta 2 Homo sapiens 55-62 25784721-2 2015 Previous studies demonstrated that salmeterol showed weak efficacy for activation of adenylyl cyclase; however, its efficacy in the complex desensitization of the beta2AR remains poorly understood. Salmeterol Xinafoate 35-45 adrenoceptor beta 2 Homo sapiens 163-170 25784721-3 2015 In this work, we provide insights into the roles played by the G protein-coupled receptor kinase/arrestin and protein kinase A in salmeterol-mediated desensitization through bioluminescence resonance energy transfer (BRET) studies of liganded-beta2AR binding to arrestin and through kinetic studies of cAMP turnover. Salmeterol Xinafoate 130-140 adrenoceptor beta 2 Homo sapiens 243-250 25784721-4 2015 First, BRET demonstrated a much reduced efficacy for salmeterol recruitment of arrestin to beta2AR relative to isoproterenol. Salmeterol Xinafoate 53-63 adrenoceptor beta 2 Homo sapiens 91-98 25324048-5 2015 Extracellular loop 3 (and specifically amino acid K305) had the largest single effect by reducing salmeterol"s affinity for the beta2-adrenoceptor by 31-fold. Salmeterol Xinafoate 98-108 adrenoceptor beta 2 Homo sapiens 128-146 26051688-1 2015 Salmeterol xinafoate is a potent and a long-acting beta2-adrenoceptor agonist. Salmeterol Xinafoate 0-20 adrenoceptor beta 2 Homo sapiens 51-69 24721141-1 2014 BACKGROUND: To evaluate the effect of variation of the Arg16Gly polymorphism of the beta2-adrenergic receptor gene on clinical response to salmeterol administered with fluticasone propionate in Chinese Han asthmatic patients. Salmeterol Xinafoate 139-149 adrenoceptor beta 2 Homo sapiens 84-109 23548523-0 2013 Influence of beta(2)-adrenergic receptor polymorphisms on asthma exacerbation in children with severe asthma regularly receiving salmeterol. Salmeterol Xinafoate 129-139 adrenoceptor beta 2 Homo sapiens 13-40 23375225-2 2013 All the compounds exhibited better beta(2)-adrenoceptor agonist activities (pEC(50)=8.47-9.20) than the reference compound salmeterol (pEC(50)=8.3) and good inhibitory activity on PDE4B2 (IC(50)=0.235-1.093 muM). Salmeterol Xinafoate 123-133 adrenoceptor beta 2 Homo sapiens 35-55 22306235-10 2012 The inhibition of TNFalpha production with salmeterol was both beta2 adrenoceptor- and protein kinase A-dependent. Salmeterol Xinafoate 43-53 adrenoceptor beta 2 Homo sapiens 63-82 23302644-9 2013 Salmeterol, a specific beta(2)-AR agonist, broke beta(1)-AR/beta(2)-AR heterooligomers, and induced beta(2)-AR-specific internalization in cells co-expressing beta(1)-AR and beta(2)-AR. Salmeterol Xinafoate 0-10 adrenoceptor beta 2 Homo sapiens 23-33 23302644-9 2013 Salmeterol, a specific beta(2)-AR agonist, broke beta(1)-AR/beta(2)-AR heterooligomers, and induced beta(2)-AR-specific internalization in cells co-expressing beta(1)-AR and beta(2)-AR. Salmeterol Xinafoate 0-10 adrenoceptor beta 2 Homo sapiens 60-70 23302644-9 2013 Salmeterol, a specific beta(2)-AR agonist, broke beta(1)-AR/beta(2)-AR heterooligomers, and induced beta(2)-AR-specific internalization in cells co-expressing beta(1)-AR and beta(2)-AR. Salmeterol Xinafoate 0-10 adrenoceptor beta 2 Homo sapiens 60-70 23302644-9 2013 Salmeterol, a specific beta(2)-AR agonist, broke beta(1)-AR/beta(2)-AR heterooligomers, and induced beta(2)-AR-specific internalization in cells co-expressing beta(1)-AR and beta(2)-AR. Salmeterol Xinafoate 0-10 adrenoceptor beta 2 Homo sapiens 60-70 23302644-10 2013 The present study demonstrated that heterooligomerization between beta(1)-AR and beta(2)-AR accelerates the isoproterenol-promoted internalization of the beta(1)-AR, and that salmeterol induces beta(2)-AR-specific internalization in Chinese hamster ovary (CHO) cells stably co-expressing beta(1)-AR and beta(2)-AR. Salmeterol Xinafoate 175-185 adrenoceptor beta 2 Homo sapiens 194-204 23302644-10 2013 The present study demonstrated that heterooligomerization between beta(1)-AR and beta(2)-AR accelerates the isoproterenol-promoted internalization of the beta(1)-AR, and that salmeterol induces beta(2)-AR-specific internalization in Chinese hamster ovary (CHO) cells stably co-expressing beta(1)-AR and beta(2)-AR. Salmeterol Xinafoate 175-185 adrenoceptor beta 2 Homo sapiens 194-204 23131487-1 2012 Salmeterol, a long-acting beta2-adrenergic receptor agonist used for the treatment of asthma and chronic obstructive pulmonary disease, has an adverse effects profile that is similar to that of salbutamol and other beta2-agonists. Salmeterol Xinafoate 0-10 adrenoceptor beta 2 Homo sapiens 26-51